Donald Trump’s proposed 100% tariffs on the pharmaceutical industry could disrupt global production and supply chains, ultimately harming patients.
The group called on the Swiss government to pursue a similar agreement to the one recently finalized by United Kingdom. The UK government stated on Thursday that the deal made Britain the only country with tariff-free access to the U.S. pharmaceutical market following Trump’s executive order.
“The tariffs imposed by the U.S. threaten global production and supply chains for pharmaceuticals, hinder research and development, and ultimately harm patients worldwide,” interpharma said in a statement posted to LinkedIn.
Under an order signed on Thursday by Donald Trump, branded pharmaceutical products imported into the United States will face tariffs unless manufacturers agree to government-negotiated drug pricing arrangements or commit to producing their medicines domestically.
Read Also – U.S. Agencies to Begin Monitoring Drinking Water for Microplastics and Pharmaceuticals
Meanwhile, a separate agreement with the United Kingdom allows tariff-free access for UK-made medicines, but includes provisions for higher prices on new drugs, including those purchased by the National Health Service.
“We call on Switzerland to advocate for a solution on par with that of the United Kingdom in its tariff negotiations with the U.S.. The goal must be to free the pharmaceutical industry from tariffs as much as possible,” interpharma said.
Chemical and pharmaceutical products accounted for more than half of Switzerland’s total exports in 2025, which reached a record 287 billion Swiss francs ($359.02 billion). Excluding gold, other precious metals, gemstones, artworks, and antiques, Swiss exports to the United States alone were valued at 54.7 billion Swiss francs.
